FIELD: medicine.
SUBSTANCE: there are offered: versions of alpha5beta1 class IgG2 antibodies of hybridomas deposited under access number in ATCC No. PTA-7421, No. PTA-7420; as well as a conjugate of the antibody and the therapeutic agent, and the marked antibody for diagnosing a disease related to alpha5beta1 expression. There are also disclosed: a coding nucleic acid; an expression vector; a recombinant cell; a method for producing the antibody; a method for detecting alpha5beta1 protein; an antibody-based pharmaceutical composition; versions for applying the antibody for treating pathological angiogenesis.
EFFECT: use of the invention provides the antibody affine to Kd 0,1 nM which can find application in treating pathology associated with angiogenesis.
37 cl, 16 dwg, 6 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| EPHRINE B2 ANTIBODIES AND METHODS FOR USING THEM | 2007 |
|
RU2451031C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | 2008 |
|
RU2514148C2 |
| ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | 2013 |
|
RU2639506C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
